Genfit SA
PAR:GNFT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Pioneer Global Group Ltd
HKEX:224
|
HK |
|
C
|
Corazon Mining Ltd
OTC:CRZNF
|
AU |
|
Histogen Inc
OTC:HSTO
|
US |
|
Zhejiang Sunriver Culture Co Ltd
SSE:600576
|
CN |
|
B
|
Beijing LabTech Instruments Co Ltd
SSE:688056
|
CN |
Genfit SA
Total Current Liabilities
Genfit SA
Total Current Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Current Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
G
|
Genfit SA
PAR:GNFT
|
Total Current Liabilities
€72.3m
|
CAGR 3-Years
22%
|
CAGR 5-Years
18%
|
CAGR 10-Years
24%
|
|
|
Valneva SE
PAR:VLA
|
Total Current Liabilities
€93.3m
|
CAGR 3-Years
-30%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
7%
|
|
|
Inventiva SA
PAR:IVA
|
Total Current Liabilities
€58.5m
|
CAGR 3-Years
24%
|
CAGR 5-Years
33%
|
CAGR 10-Years
N/A
|
|
|
Cellectis SA
PAR:ALCLS
|
Total Current Liabilities
$145.8m
|
CAGR 3-Years
45%
|
CAGR 5-Years
23%
|
CAGR 10-Years
6%
|
|
|
DBV Technologies SA
PAR:DBV
|
Total Current Liabilities
$58m
|
CAGR 3-Years
25%
|
CAGR 5-Years
2%
|
CAGR 10-Years
14%
|
|
|
Abivax SA
PAR:ABVX
|
Total Current Liabilities
€94m
|
CAGR 3-Years
43%
|
CAGR 5-Years
24%
|
CAGR 10-Years
30%
|
|
Genfit SA
Glance View
Genfit SA is a biopharmaceutical company involved in drug discovery and development for the early diagnosis, prevention and treatment of cardiometabolic diseases. The company is headquartered in Loos, Hauts-De-France. The company went IPO on 2006-12-19. The firm is focused on contributing to bringing medicines to market for patients with metabolic, inflammatory, autoimmune and fibrotic diseases that affect the liver, such as Nonalcoholic steatohepatitis (NASH) or the bowel, such as the inflammatory bowel disease. The firm targets a number of therapeutic areas, which includes nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBC), NASH diagnosis, NASH-induced fibrosis and IL-17 dependent autoimmune diseases. The Company’s research programs develop diversified pipeline of drug candidates, including Elafibranor in NASH, which is in phase III; Elafibranor in PBC, which is in phase II; In-Vitro diagnostic test for NASH and Nitazoxanide in fibrosis, which is still in clinical stage, among others.
See Also
What is Genfit SA's Total Current Liabilities?
Total Current Liabilities
72.3m
EUR
Based on the financial report for Dec 31, 2025, Genfit SA's Total Current Liabilities amounts to 72.3m EUR.
What is Genfit SA's Total Current Liabilities growth rate?
Total Current Liabilities CAGR 10Y
24%
Over the last year, the Total Current Liabilities growth was -4%. The average annual Total Current Liabilities growth rates for Genfit SA have been 22% over the past three years , 18% over the past five years , and 24% over the past ten years .
